Nurix Stock

nurixtx.comHealthcare / BioTech & PharmaFounded: 2012Funding to Date: $48.38MM

Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels by controlling ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases.

Register for Details

For more details on financing and valuation for Nurix, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Nurix.

Register Today

Team

Management Team

Nancy Pryer Ph.D
Chief Development Officer
John Kuriyan Ph.D
Co-Founder
Pierre Beaurang Ph.D
Chief Business Officer
Michael Rape Ph.D
Co-Founder
Arthur Sands Ph.D
Chief Executive Officer & Board Member
Arthur Weiss MD
Co-Founder

Board Members

David Lacey MD
Arthur Sands Ph.D
Robert Tjian Ph.D
The Column Group
Timothy Kutzkey Ph.D
The Column Group
Jeffrey Tong Ph.D
Third Rock Ventures

Other companies like Nurix in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Nurix Therapeutics Announces Key Additions to its Board of Directors
Xconomy: With $45M Nurix Deal, Gilead Enters Crowded Protein Degradation Field
Gilead Sciences is turning to Nurix Therapeutics in an effort to discover new drugs that harness the cellular machinery our bodies use to dispose of
Updated on: Sep 21, 2023